- Conditions
- Prostatic Neoplasms
- Interventions
- RTVP-1 Gene
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2041–2064
of 7,396
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza
- Interventions
- A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel)
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Durham, North Carolina
- Conditions
- Brain Imaging, Whole Body Imaging
- Interventions
- 18F-FDG, 18F-AV1451, Siemens E7 Reconstruction Tool
- Drug · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- carboplatin, 7-hydroxystaurosporine, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Infections, Pediatrics
- Interventions
- Ceftaroline fosamil, Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam, Cephalexin or Clindamycin or Linezolid
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 2 Months to 17 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Orange, California • San Diego, California + 23 more
- Conditions
- Healthy
- Interventions
- Abemaciclib, Placebo, Loperamide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Evansville, Indiana
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Durvalumab, Stereotactic Body Radiation Therapy (SBRT), Standard of Care Therapy
- Drug · Radiation · Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado
- Conditions
- Parkinson's Disease
- Interventions
- PF-06649751
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Fountain Valley, California • Long Beach, California • Englewood, Colorado + 10 more
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Paclitaxel
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Miami, Florida • Chicago, Illinois • Zion, Illinois + 1 more
- Conditions
- Advanced Unresectable Solid Tumors, BRAF-mutated Tumors
- Interventions
- FORE8394
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Orange, California • Stanford, California + 9 more
- Conditions
- Healthy
- Interventions
- Pomalidomide, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- MDS, Myelodysplastic Syndromes
- Interventions
- APR-548 + Azacitidine
- Drug
- Lead sponsor
- Aprea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Boston, Massachusetts • Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- nesvacumab (REGN910/ SAR307746)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- San Francisco, California • San Antonio, Texas
- Conditions
- Renal Impairment
- Interventions
- JNJ-42847922
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Knoxville, Tennessee
- Conditions
- Germ Cell Tumors, Testis Cancer, Testicular Cancer, Embryonal Carcinoma, Nonseminomatous Germ Cell Tumor
- Interventions
- Brentuximab Vedotin
- Drug
- Lead sponsor
- Nabil Adra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • New York, New York
- Conditions
- Melanoma, Squamous Cell Carcinoma of Head and Neck
- Interventions
- IO102-IO103, Pembrolizumab KEYTRUDA®
- Drug
- Lead sponsor
- IO Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Richmond, Virginia
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Cusatuzumab, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- OncoVerity, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 11
- States / cities
- Duarte, California • Louisville, Kentucky • Detroit, Michigan + 7 more
- Conditions
- Healthy
- Interventions
- PER977, Placebo, Heparin Sodium
- Drug
- Lead sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- Interventions
- Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus
- Other · Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Advanced Solid Tumors
- Interventions
- M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen
- Drug · Radiation
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT)
- Drug · Radiation · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 10
- States / cities
- Duarte, California • Stanford, California • Basking Ridge, New Jersey + 7 more
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Blood Cancer, Hematological Malignancy
- Interventions
- MT-3724 Phase 1, MT-3724 Phase 2
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Whittier, California • Jacksonville, Florida + 12 more
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- fluorouracil, sodium phenylbutyrate, indomethacin, recombinant interferon gamma
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Treatment Resistant Depression
- Interventions
- ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
- Drug
- Lead sponsor
- Alar Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more